China Resources Double-Crane Pharmaceutical's subsidiary received a CEP certificate for sodium propionate raw material.

17:28 01/07/2026

China Resources Shuanghe (600062.SH) announced recently that its subsidiary, China Resources Shuanghe Xiangzhong Medicine (Hunan) Co., Ltd., has received the Certificate of Suitability for Sodium Valproate API of European Pharmacopoeia (EP) issued by the European Directorate for the Quality of Medicines & HealthCare (EDQM). Sodium valproate is a medication used to treat mental disorders, mainly epilepsy and mania.

China Resources Double-Crane Pharmaceutical (600062.SH) announced that its holding subsidiary, China Resources Double-Crane Pharmaceutical Xiangzhong Pharmaceutical (Hunan) Co., Ltd., has received a Certificate of Suitability for Sodium Valproate API (CEP certificate) issued by the European Directorate for the Quality of Medicines and Healthcare (EDQM). Sodium Valproate is a medication used for treating mental illnesses, primarily for epilepsy and manic episodes.

ZHEJIANGEXPRESS (00576) is undergoing a stock absorption merger with Zhejiang Oceanking Development and has obtained approval from the China Securities Regulatory Commission to issue A shares under special authorization.

IMPRO PRECISION (01286): Zhang Yongfeng appointed as Executive Director and member of the Sustainable Development Committee.

KEEP(03650): Wong Pui Kiu appointed as joint company secretary and legal process agent

IMPRO PRECISION (01286): Zhang Yongfeng appointed as Executive Director and member of the Sustainable Development Committee.

KEEP(03650): Wong Pui Kiu appointed as joint company secretary and legal process agent